The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions
No Thumbnail Available
Date
2022-07-01
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) developed consensus statements on pre-invasive vulvar lesions in order to improve the quality of care for patients with vulvar squamous intraepithelial neoplasia, vulvar Paget disease in situ, and melanoma in situ. For differentiated vulvar intraepithelial neoplasia (dVIN), an excisional procedure must always be adopted. For vulvar high-grade squamous intraepithelial lesion (VHSIL), both excisional procedures and ablative ones can be used. The latter can be considered for anatomy and function preservation and must be preceded by several representative biopsies to exclude malignancy. Medical treatment (imiquimod or cidofovir) can be considered for VHSIL. Recent studies favor an approach of using imiquimod in vulvar Paget's disease. Surgery must take into consideration that the extension of the disease is usually wider than what is evident in the skin. A 2 cm margin is usually considered necessary. A wide local excision with 1 cm free surgical margins is recommended for melanoma in situ. Following treatment of pre-invasive vulvar lesions, women should be seen on a regular basis for careful clinical assessment, including biopsy of any suspicious area. Follow-up should be modulated according to the risk of recurrence (type of lesion, patient age and immunological conditions, other associated lower genital tract lesions).
Description
Funding Information: CC: advisory boards for GSK and MSD, support for clinical research from Roche and TherAguiX; DQ: advisory boards for Mimark; EJ: advisory boards for MSD and Roche Diagnostics, grants for traveling from MSD; JB support for clinical research from Merck (Galilee Medical Center Research Fund), member of speakers’ bureau for MSD Israel. BET, BEE, CS, DH, FB, FP, JZ, LW, MB, MEC, MG, MP, MVB, NG, OR, PVB, VK, XC: no conflict of interest. Publisher Copyright: © IGCS and ESGO 2022.
Keywords
3.2 Clinical medicine, 1.1. Scientific article indexed in Web of Science and/or Scopus database, Oncology, Obstetrics and Gynaecology
Citation
Preti, M, Joura, E, Vieira-Baptista, P, Van Beurden, M, Bevilacqua, F, Bleeker, M C G, Bornstein, J, Carcopino, X, Chargari, C, Cruickshank, M E, Erzeneoglu, B E, Gallio, N, Heller, D, Kesic, V, Reich, O, Stockdale, C K, Esat Temiz, B, Woelber, L, Planchamp, F, Zodzika, J, Querleu, D & Gultekin, M 2022, 'The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions', International Journal of Gynecological Cancer, vol. 32, no. 7, pp. 830-845. https://doi.org/10.1136/ijgc-2021-003262